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chromium stent, abluminally coated with a thin (4.4 mg) PLA-PLGA polymeric layer,
eluted with low-dose sirolimus. The present study aims to evaluate the safety and
efﬁcacy proﬁle of the novel drug-eluting-stent in a very high-risk population treated in
a tertiary university hospital.
Methods: Up to May 2014, a total of 276 all-comers, without any speciﬁc anatomical
or clinical restriction, have been treated with the novel sirolimus-eluing stent im-
plantation and comprise this study population. Patients were maintained in dual an-
tiplatelet therapy for a minimum of 6 months and aspirin was prescribed indeﬁnitely
thereafter. Patients have been clinically followed-up at 1, 6 and 12 months post-
procedure.
Results: For the entire cohort, a total of 342 lesions were treated with 429
Inspiron stents. The included population had a very high risk proﬁle. Overall
53.6% were diabetics, 70.7% had multivessel disease, 39.5% were admitted with
acute coronary syndromes, heart failure was present in 16.7%, and 19.2% had
previous coronary surgery. Most lesions were type B2/C (79.8%), 31.7% were
bifurcations, and 17.6% were restenosis of a previously implanted stent. After a
mean follow-up of 136  101 days, the rate of target lesion-related death was
0.5%, myocardial infarction 4.9%, and target lesion revascularization 2.3%. There
was only one episode of (probable) stent thrombosis (total any thrombosis rate at
140 days was 0.4%).
Conclusions: The interim results of this real life registry demonstrate promising mid-
term safety and efﬁcacy results for the novel Inspiron sirolimus-eluing stent in the
treatment of highly complex patients.TCT-609
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Background: The current study aimed to compare the 1-year clinical outcomes after
implantation of the Cre8 (CID/Alvimedica, Saluggia, Italy) amphilimus, polymer-free
stent versus new generation everolimus eluting stents (EES) in a real-world patient
registry.
Methods: A total of 150 consecutive patients (197 lesions) treated with Cre8 between
January 2011 and August 2013 in 4 Italian centers were included. These were pro-
pensity matched for baseline characteristics with 150 patients (201 lesions) treated
with new generation EES during the same period. Primary outcome was one year
major adverse cardiovascular events (MACE), deﬁned as all-cause death, myocardial
infarction (MI) and target-vessel revascularization (TVR).
Results: Both groups had similar baseline characteristics including age (67.89.8
Cre8 vs. 66.99.7 EES years, p¼0.393), male gender (84% Cre8 vs. 86.7% EES,
p¼0.514) diabetes (28% Cre8 vs. 27.3% EES, p¼0.972), previous PCI (56% Cre8
vs. 58%EES, p¼0.726), previous CABG (22.0% Cre8 vs. 22.7% EES, p¼1.000)
and previous MI (33.3% Cre8 vs. 31.3% EES, p¼0.711). With regards to lesion
characteristics there was a higher prevalence of B2/C lesions in the EES group
(61.6% vs. 85.4%, P< 0.001) whereas the number of restenotic lesions was similar
(13.7% Cre8 vs. 11.0% EES, p¼0.413). Total stent length per patient
(35.425.4mm Cre8 vs. 36.626.3mm EES, p¼0.667) and SYNTAX score
(15.429.9 Cre8 vs. 15.2811.5 EES, p¼0.920) were similar in the two cohorts. At
one year, MACE rate (7.4% Cre8 vs. 10.2% EES, p¼0.261), all-cause mortality
(1.3% Cre8 vs. 1.4% EES, p¼0.823), TVR (5.2% Cre8, 8.8% EES. P¼0.169) and
target lesion revascularization-TLR (3% Cre8 vs. 7.4% EES, p¼0.108) were not
signiﬁcantly different between the two groups. There was a trend for reduced lesion
TLR at one year (3.5% Cre8, vs. 7.3% EES, p¼0.055) however this was lost after
adjustment for AHA lesion type. In patients with diabetes (Cre8 n¼42; EEE n¼41)
the 1-year TLR was 2.5% in the Cre8 group versus 14.6% in the EES group
(p¼0.056).
Conclusions: The Cre8 stent is safe and clinically effective, with similar 1-year
MACE, TVR and TLR rates as new generation EES in a “real-world” patient
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Background: The DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
System (NEBCSS) is a drug-eluting bioresorbable scaffold combining a PLLA-based
scaffold coated with a biodegradable polylactide-based polymer and Novolimus, a
macrocyclic lactone mTOR inhibitor. The DESolve NX study is a prospective,
multicenter evaluation of the safety and efﬁcacy of the DESolve NEBCSS in patients
with single, de novo, native coronary artery lesions.
Methods: 126 patients receiving the study device were evaluated for multiple
clinical endpoints including: major adverse cardiac events-a composite endpoint
of cardiac death, target vessel MI, or clinically-indicated target lesion revascular-
ization, and stent thrombosis. Endpoints are assessed at 1, 6 and 12 months and
annually to 5 years. All patients underwent angiographic assessment at 6 months
with a subset of patients having IVUS and OCT at 6 months and MSCT at
12 months.
Results: Mean age at baseline was 62 years, 32% were females, and 21% diabetics.
Pre-procedure lesion length was 11.2 mm, RVD was 3.06 mm, and 18.3% of patients
had moderate-to-heavy calciﬁcation. Six-month QCA imaging demonstrated low
mean in-scaffold late lumen loss (0.20 mm), 18.3 %DS and an MLD of 2.45 mm.
Serial IVUS imaging (baseline and 6 months) demonstrated a signiﬁcant increase in
mean lumen (D 9.0%, p ¼ < 0.001) and scaffold areas (D 15.7%, p ¼ < 0.001) and
low % volume obstruction (5.05%); and serial OCT imaging demonstrated a signif-
icant increase in scaffold area (D 16.9 %, p ¼ < 0.001) and 98.78% endothelial
coverage of the scaffold at 6 months. Twelve-month MSCT results demonstrated that
lumen dimensions (21.8 %DS and 2.3mm MLD) were maintained from 6 to 12
months. Clinical events remained low (MACE ¼ 5.69% at 12 months) with no reports
of deﬁnite stent thrombosis.
Conclusions: DESolve demonstrated safety and efﬁcacy with low late lumen loss.
Serial imaging assessments indicated early vessel restoration at 6 months. At 12
months, the clinical event rate was low, and MSCT demonstrated good luminal
patency. Imaging endpoints and 2-year clinical results will be presented.TCT-611
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Background: Bioresorbable scaffold (BVS, Absorb, Abbott Vascular) are currently
used also for the treatment of acute coronary syndromes, but data on the outcome at
the level of the culprit plaque are still missing. Characteristics of a stable plaque
include a thick ﬁbrous cap and vasodilation in response to endothelium-dependent
vasodilators.
Methods: We describe the 12-months clinical, morphological and functional
outcome after BVS implantation for the treatment of culprit lesions in consecutive
patients with myocardial infarction. Vasomotion was assessed with infusions of
endothelium-dependent acetylcholine and endothelium-independent nitroglycerin.7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
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(OCT, St Jude).
Results: 71 Patients (77 lesions, 60+/-13 years old, 57 males, 7 diabetics) underwent
coronary angiography at 12 months after BVS implantation for acute coronary syn-
dromes (42 NSTEMI, 29 STEMI). OCT was performed in 65 lesions; endothelial
function (intracoronary infusions of three different doses of acetylcholine) and
endothelium-independent vasodilation (intracoronary nitroglycerin, 200microgr) were
tested in 54 patients. Results The culprit lesion was identiﬁed in all cases with OCT.
The minimum thickness of the ﬁbrous cap covering the lesion was 0 to 550 micro-
meter (mean 232+/-139microm). Incomplete BVS expansion was evidenced in 20
cases and malapposition in 15. The minimum lumen area was 2 to 11 mm2. There
were 3 cases of in-BVS restenosis, maximal neointima thickness was 370+/-
220microm), uncovered struts were observed in 12 lesions. Vasodilation beyond the
minimum resolution of angiography was observed in 40% of the lesions, and vaso-
constriction in 30%.
Conclusions: 12 months after BVS implantation, the presence of a ﬁbrotic cap and of
phisiologic vasodilation in response to endothelium-dependent acetylcholine conﬁrm
an effective stabilization of the culprit plaque. These data provide a rationale for the
use of BVS in the setting of culprit lesions and the basis for a long-term randomized
study comparing BVS with traditional metal stents.
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Background: To date no data exist on clinical outcomes of patients with calciﬁed
lesions treated with bioresorbable vascular scaffolds (BVS).
Methods: We analyzed 8-month clinical outcome data of consecutive patients with at
least one calciﬁed lesion [deﬁned as calcium arc>60o on IVUS (performed in 78.6%
of cases) or in the absence of IVUS at least moderate lesion calciﬁcation on angi-
ography] treated with BVS between May 2012 and May 2014. Primary outcome was
major adverse cardiovascular event [MACE: deﬁned as all-cause death, myocardial
infarction (MI) and target-vessel revascularization (TVR)] rate, at median follow up
time.
Results: Out of a total of 163 patients treated with BVS, 62 (38%) had at least one
calciﬁed lesion. Mean age of the latter was 63.810.5 years and 54 (87.1%) were
male. There were 22 (35.5%) patients with diabetes, 3 (4.8%) patients with previous
CABG and 31 (50%) with previous PCI. Mean SYNTAX score was 18.899.7,
whereas left ventricular ejection fraction was 55.57.8%. Mean total stent length
per patient was 53.329.3mm. Of a total of 76 calciﬁed lesions 82.9% were AHA
type B2/C, 3.9% were in-stent restenosis, 5.3% were chronic total occlusions and
51.3% were bifurcation lesions. Average calcium arc angle was 189.8101.2o. Left
anterior descending was involved in 67.1% of lesions, circumﬂex in 19.7%, right
coronary artery in 11.8% and left main in 1.3%. Predilatation was performed in all
cases with conventional balloons whereas a scoring balloon was used in 26.3% of
cases and rotablation in 11.8%. Postdilatation was used in all but one case (98.7%),
with an average maximum pressure of 20.75.1atm. Minimal luminal area (MLA)
increased from 3.181.34 pre-procedure to 6.41.65 mm2(minimum stent area)
post BVS implantation, p< 0.001. At median follow up of 8.7 (4.9 to 13.4) months
4 (6.5%) MACE occurred. There were no deaths observed, one MI (1.6%), 3 (4.8%)
cases of TLR, 4 (6.5%) of TVR and one case (1.6%) of deﬁnite late stent
thrombosis.
Conclusions: Excellent short term results are observed in patients with calciﬁed
lesions treated with BVS. Meticulous lesion preparation is essential.
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Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (Absorb, Abbott Vascular, Santa Clara, CA) has been previously
demonstrated with clinical data up to 5 years (Cohort A), 3 years (Cohort B), 2
years (EXTEND). ABSORB FIRST is designed for post-approval surveillance of
Absorb BVS used in complex lesions and patients typically treated in real-world
settings.
Methods: ABSORB FIRST is a prospective, multi-center, global registry to eval-
uate the safety and effectiveness of Absorb in the real-world, all-comer population
as per Instructions for Use. This study aims to evaluate 1800 patients with de novo
lesions at approximately 90 sites in more than 20 countries worldwide. TreatmentJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Stestrategy is determined by physician and limited to lesions in vessels without prior
intervention. The key clinical endpoints include scaffold thrombosis, cardiac death,
myocardial infarction, revascularization, MACE, TLF, and TVF. All reportable
adverse events are 100% monitored and clinical events are independently
adjudicated.
Results: This is the largest report of 30-day post-PCI clinical results in Absorb-
treated patients from a single trial (ABSORB FIRST, N¼1,200). Compared to the
Cohort A, B and EXTEND these patients are at greater risks of CAD, higher rates
of dyslipidemia (65.8% %), hypertension (64.8%), diabetics (25.1%), family
history of premature CAD (37.9%), multi-vessel disease (48.4%), and prior car-
diac interventions (24.4%). There is also a high proportion of patients with Class
B2/C lesions (48.3 %), moderate/severe calciﬁed lesions (18.6%), bifurcations
(12.1%), total occluded lesions (10.4%), ostial lesions (6.2%). The mean lesion
length is 18.6  9.2 mm. The device success and procedure success rates were
98.4 % and 97.9 %, respectively. Subgroup analyses by patient and lesion com-
plexities, access site, and physician’s treatment techniques and implantation
experience with BVS will also be reported. Clinical results up to 30 days will be
discussed.
Conclusions: The interim results from this large, global registry demonstrate excellent
acute and sub-acute performance of Absorb in complex, real-world patients.TCT-614
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Background: The process of bioresorption following Absorb bioresorbable
vascular scaffold (Absorb, Abbott Vascular) placement has been investigated by op-
tical coherence tomography (OCT) and intravascular ultrasound imaging modalities;
however, the details of histomorphological changes within the strut remain poorly
characterized. We present detailed histological characterization of the strut composi-
tion in porcine coronary arteries from 6 to 48 months (mo).
Methods: A total of 32 Absorb in swine coronary arteries (29 animals) from 8 time
points (6, 12, 18, 24, 30, 36, 42, and 48 mo, 4 Absorb from each time point) were
evaluated using histologic and immunohistological stains (Figure).
Results: Struts are of stable morphology through 18 mo, being unstained and easily
identiﬁed under polarized light (Figure). Thereafter, there is rapid decline in bire-
fringence of strut sites and color changes marked by increased proteoglycan staining
by Movat and Alcian blue (blue-green, 24 mo) and increasing eosinophilia by H&E
(30 mo). These changes correspond to the absorption and inspissation of proteins
(presence of albumin). Strut sites are eventually composed of a provisional matrix that
matures from collagen Type III integration (36 mo) to eventual replacement by
smooth muscle cells and collagen Type I at 42 to 48 mo, demonstrating an increasing
integration of scaffold into the arterial tissue.
Conclusions: Detailed histological characterization of the Absorb struts provides
insight into the process of bioresorption and integration that may be correlated to
changes observed by in vivo imaging modalities such as OCT.nts - Drug-eluting: Bioresorbable Scaffolds B179
